Literature DB >> 14615154

Monoclonal antibodies that neutralize HEV recognize an antigenic site at the carboxyterminus of an ORF2 protein vaccine.

Darren J Schofield1, Robert H Purcell, Hanh T Nguyen, Suzanne U Emerson.   

Abstract

In order to obtain monoclonal antibodies that might have prophylactic applications and to understand better the immune response to hepatitis E virus (HEV), we used phage display to isolate chimpanzee antibodies to HEV. The panning antigen was an two open reading frame (ORF2) recombinant protein that elicits a broadly protective immune response in vaccinated monkeys. Two major antigenic sites were identified on the ORF2 protein: one site was not accessible on the surface of infectious virions but the other site was accessible to antibodies and was recognized specifically by antibodies that neutralize the virus.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14615154     DOI: 10.1016/j.vaccine.2003.07.008

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  21 in total

1.  Structure of hepatitis E virion-sized particle reveals an RNA-dependent viral assembly pathway.

Authors:  Li Xing; Tian-Cheng Li; Naoyuki Mayazaki; Martha N Simon; Joseph S Wall; Mary Moore; Che-Yen Wang; Naokazu Takeda; Takaji Wakita; Tatsuo Miyamura; R Holland Cheng
Journal:  J Biol Chem       Date:  2010-08-18       Impact factor: 5.157

2.  ORF3 protein of hepatitis E virus is not required for replication, virion assembly, or infection of hepatoma cells in vitro.

Authors:  Suzanne U Emerson; Hanh Nguyen; Udana Torian; Robert H Purcell
Journal:  J Virol       Date:  2006-08-23       Impact factor: 5.103

3.  Chimeric hepatitis E virus-like particle as a carrier for oral-delivery.

Authors:  Pitchanee Jariyapong; Li Xing; Nienke E van Houten; Tian-Cheng Li; Wattana Weerachatyanukul; Benjamin Hsieh; Carlos G Moscoso; Chun-Chieh Chen; Masahiro Niikura; R Holland Cheng
Journal:  Vaccine       Date:  2012-10-26       Impact factor: 3.641

4.  Dynamics of 8G12 competitive antibody in "prime-boost" vaccination of Hepatitis E vaccine.

Authors:  Xing Wu; Pan Chen; Huijuan Lin; Yao Su; Xiaotian Hao; Yufeng Cao; Li Li; Fengcai Zhu; Zhenglun Liang
Journal:  Hum Vaccin Immunother       Date:  2017-03-08       Impact factor: 3.452

5.  Phage-displayed peptides that mimic epitopes of hepatitis E virus capsid.

Authors:  Osmany Larralde; Juraj Petrik
Journal:  Med Microbiol Immunol       Date:  2017-04-22       Impact factor: 3.402

Review 6.  Hepatitis E: an overview and recent advances in vaccine research.

Authors:  Ling Wang; Hui Zhuang
Journal:  World J Gastroenterol       Date:  2004-08-01       Impact factor: 5.742

7.  A single amino acid substitution changes antigenicity of ORF2-encoded proteins of hepatitis E virus.

Authors:  Jiu-Hong Liang; Xing Dai; Chen Dong; Ji-Hong Meng
Journal:  Int J Mol Sci       Date:  2010-08-12       Impact factor: 5.923

8.  Biological and immunological characteristics of hepatitis E virus-like particles based on the crystal structure.

Authors:  Tetsuo Yamashita; Yoshio Mori; Naoyuki Miyazaki; R Holland Cheng; Masato Yoshimura; Hideaki Unno; Ryoichi Shima; Kohji Moriishi; Tomitake Tsukihara; Tian Cheng Li; Naokazu Takeda; Tatsuo Miyamura; Yoshiharu Matsuura
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-20       Impact factor: 11.205

9.  Mutations within potential glycosylation sites in the capsid protein of hepatitis E virus prevent the formation of infectious virus particles.

Authors:  Judith Graff; Yi-Hua Zhou; Udana Torian; Hanh Nguyen; Marisa St Claire; Claro Yu; Robert H Purcell; Suzanne U Emerson
Journal:  J Virol       Date:  2007-11-21       Impact factor: 5.103

Review 10.  Hepatitis E vaccines: progress and prospects.

Authors:  Harald Claus Worm; Gerhard Wirnsberger
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.